🇸🇪 Cancer in Sweden

Socialstyrelsen published its fact sheet for 2024 on 4 November 2025. The register has run since 1958, reporting is a legal duty under the health data register law and Socialstyrelsen's regulations, and a notification is normally complete only when both the treating clinic and the pathology laboratory have reported. About 99 per cent of tumour records are confirmed by microscopy. In women the commonest cancers were breast (8,803 diagnoses, 1,328 deaths), non-melanoma skin cancer (5,420), colon (2,743 and 1,000 deaths), melanoma (2,671) and lung (2,511 and 1,965 deaths). In men they were prostate (10,782 diagnoses, 2,043 deaths), non-melanoma skin (6,760), melanoma (2,931), lymphoma, leukaemia and related cancers together (2,792) and colon (2,745). Socialstyrelsen notes that the fall in reported cases in 2024 probably reflects late reporting rather than less cancer: the latest year is revised upwards the following year. Basal cell carcinoma is counted separately, at about 50,000 people a year, and is not in these totals.

Socialstyrelsen measures change as the average annual percentage change in age-standardised incidence between 2005 and 2024. Lung cancer rose 1.5 per cent a year in women and fell 1.8 per cent a year in men, reaching 46 per 100,000 in women and 37 in men. Non-melanoma skin cancer rose 6 per cent a year in women and 4.5 per cent in men; melanoma 4.2 and 3.9 per cent. Pancreatic cancer rose 2.3 per cent a year in women and 1.7 per cent in men, colon cancer 0.6 to 0.7 per cent in both, and prostate cancer fell 1 per cent a year. Pancreatic cancer caused 1,007 deaths in women and 1,046 in men in 2024, more than colon cancer in either sex, on about 850 diagnoses in each.

The 2024 fact sheet divides the country into Statistics Sweden's 3,363 regional statistical areas, grouped into five types by education, income and welfare dependence. Age-standardised cancer mortality runs the opposite way to incidence. Among women, lung cancer incidence was 55 per 100,000 in areas with major socioeconomic challenges against 38 in the most advantaged areas, and lung cancer mortality 45 against 23. Among men, lung cancer incidence was 63 against 31 and mortality 54 against 27, while prostate cancer incidence was 149 against 259. Melanoma and non-melanoma skin cancer were more than twice as common in the advantaged areas in both sexes; in women the death rates from them were similar, while in men melanoma was more than twice as common a cause of death in the advantaged areas.

Cancer i siffror 2023 uses 2021 data. It gives relative ten-year survival of 72.8 per cent for men and 71.6 per cent for women, a total prevalence of 292,051 men and 317,040 women at 31 December 2021, and a five-year prevalence of about 240,000 people. Relative survival is an estimate of the share of patients who have not died of their cancer, so it excludes deaths from other causes; these all-cancer figures mix cancers with very different outlooks and should not be read as anyone's individual outlook. Cancerfonden summarises the change since 1970 as a move from three in ten alive ten years after diagnosis to about seven in ten. Socialstyrelsen's own fact sheet for 2024 does not publish survival.

Socialstyrelsen estimated the gap by linking the cause of death and patient registers for 2005 to 2022. Of 509,832 cancer-related causes of death, 76 per cent matched a diagnosis in the cancer register and 17 per cent one in the patient register only. The confirmed cases missing from the register averaged 3,958 a year, which would add 6.4 per cent to the count; the shortfall fell from 8.0 per cent in 2005 to 2013 to 4.8 per cent in 2014 to 2022, and was 12.3 per cent among people diagnosed at 80 or older against 2.7 per cent below 80. Its quality page singles out pancreatic and lung cancer, where about 500 cases a year reported on death certificates have never been notified. Socialstyrelsen states that systematic follow-up would probably need a change in the law.

SKR, the association of municipalities and regions, describes health care as financed mainly by the regions and municipalities themselves through their own power to tax, together with state grants and, to some extent, patient fees. Health care made up 88 per cent of the regions' costs in 2025, of a total of about 492.6 billion kronor. Regions decide how much care to provide and how it is organised, including what they pay private providers working with public money. The six health-care regions agree price lists and where particular specialities sit, and each has at least one regional hospital. A cancer patient's treatment is therefore decided and paid for by a region, which is why waiting times, screening and access to new hospital drugs are measured and published region by region.

The outpatient cap (högkostnadsskydd) counts from the first visit; once 1,450 kronor has been paid the patient receives a frikort, valid in all regions, and a region may set a lower amount. It does not usually cover certificates, health checks, copies of records or the daily charge for inpatient care. The pharmaceutical benefit has its own twelve-month period: the patient pays full price up to 2,000 kronor, then the share falls in steps, with 25, 75 and 90 per cent discounts, until 3,800 kronor has been paid, after which subsidised prescription medicines are free for the rest of the period. These caps cover prescription medicines collected at a pharmacy; cancer medicines given by staff in hospital or clinic are bought by the region directly and are not part of the pharmacy benefit.

Cancerfonden's report of 14 October 2026 modelled breast and colorectal cancer. For women aged 40 to 64 with breast cancer, reduced income was estimated at a little over 345,000 kronor, mostly from sick leave, offset by about 200,000 kronor of sick pay, sickness benefit and activity compensation, with about 21,000 kronor of added costs for care fees, medicines, dental care, aids and travel: a burden of about 170,000 kronor, about 135,000 of it in the first two years. For colorectal cancer at the same ages the total was also about 170,000 kronor. Above 65, where income is less affected, the estimated burden was about 35,000 kronor for breast cancer and 50,000 for colorectal cancer, mostly in costs. The sickness insurance ceiling in 2026 is an income of 600,000 kronor a year, so higher earners lose a larger share. About 12,000 people with cancer receive sickness benefit each year.

Under the law on pharmaceutical benefits (2002:160) TLV's expert board decides on applications, and the ordinance (2002:687) requires a decision within 180 days of a complete application. TLV's assessments follow the ethical platform parliament set for health-care priorities: equal human dignity, need and solidarity, and a reasonable relation between cost and benefit. Severity is graded low, moderate, high or very high; the agency states that the higher the severity, the higher the cost per quality-adjusted life year (QALY) it is reasonable to pay, and that for particularly rare conditions of very high severity it may accept more. It takes a limited societal perspective and does not, as a starting point, count productivity gains from returning to work, because doing so would favour people who can work. One cancer example: for erdafitinib (Balversa) in previously treated FGFR3-altered urothelial cancer, TLV graded the severity very high, estimated about 950,000 kronor per QALY against vinflunine with sensitivity analyses from about 750,000 to 1.14 million, and noted most of them were below what it normally accepts at that severity.

Rådet för nya terapier has a member from each health-care region, a chair, experts in health economics and medical ethics, co-opted oncology, paediatric, legal and communication expertise, and two patient advisers. It decides which medicines go into the national process of ordered introduction; for those, it orders a health-economic assessment from TLV, decides the willingness to pay, can send the regions' negotiators to the company, and then issues a recommendation to all regions. TLV's planned and ongoing hospital-drug assessments for the council include datopotamab deruxtecan and sacituzumab govitecan in triple-negative breast cancer, tarlatamab in small-cell lung cancer, zanidatamab in biliary cancer and teclistamab with daratumumab in myeloma. Where a company and the regions agree, three-party talks with TLV can end in a side agreement under which the company repays part of the cost; the regions report more than 140 such joint agreements and say almost all are needed for the drugs to count as cost-effective. On 1 September 2026 three cancer medicines, inavolisib and capivasertib in breast cancer and lazertinib in lung cancer, entered the cost cap, decisions the regions say were largely made possible by such agreements.

The FINOSE collaboration began in 2018 between the HTA agencies of Finland, Norway and Sweden, added Denmark in 2023 and Iceland in 2024, and was renamed Joint Nordic HTA-Bodies in June 2024; it assesses relative effect and cost-effectiveness together, mainly for hospital drugs, while price and use are decided nationally. The EU HTA Regulation (2021/2282) has applied since 12 January 2025; its first phase covers cancer medicines and advanced therapy medicinal products, an estimated 30 products a year, rising to all centrally authorised medicines, about 120 a year, from 2030. The joint clinical assessment reports contain no value judgement, so TLV still interprets the relative effect itself, and because Sweden uses health economics the cost-effectiveness judgement remains national. TLV and SBU reported to the government on 2 November 2026 on how Sweden takes part.

Under the EU centralised procedure, medicines containing a new active substance for cancer must be evaluated by the European Medicines Agency, as must all biotechnology products, advanced therapies and designated orphan medicines. After a valid application the evaluation by the Committee for Medicinal Products for Human Use takes up to 210 days, and the European Commission then has 67 days to decide; the authorisation is valid across the European Economic Area. Because the scientific approval is European, the time between approval and treatment for a Swedish patient is set mainly by the national steps that follow, TLV's subsidy decision and the regions' NT council, which the section above describes.

The pathways (standardiserade vårdförlopp, SVF) were started in 2015 by the government and the regions to cut waiting and uncertainty and to make care more equal. Each begins with a defined well-founded suspicion, for breast cancer a list of findings such as a suspicious lump in the breast or a new nipple retraction, after which the patient is referred straight into the pathway. The breast cancer pathway's national lead time, from the decision of well-founded suspicion to the start of first treatment by surgery, drugs or radiotherapy, was extended from 28 to 35 calendar days. Two national goals apply: that 70 per cent of all new cancers in a diagnosis with a pathway are investigated through it, and that 80 per cent of patients start treatment within the lead time. Regions report start and stop dates to SKR's waiting-time database and, from 1 July 2025, also to Socialstyrelsen; part of the state money the regions receive for the pathways depends on reporting and on meeting the inclusion goal.

RCC's annual report for 2025, dated 27 March 2026, records 148,441 completed pathways. The inclusion goal was met for 16 of 27 pathways. Three regions, all of which changed electronic records systems during the period, missed the 70 per cent goal for the first half of the year, and four missed it for the year as a whole. By first treatment, 46 per cent of surgical patients started in time (44 per cent in 2024), 35 per cent of radiotherapy patients (32 per cent) and 50 per cent of drug-treated patients (unchanged). In eight regions at least 50 per cent started in time. RCC found no clear difference between women and men nationally. Patient surveys give a good overall impression of the pathways. In 2026 every region must review the patients who waited more than 50 per cent longer than the lead time in the myeloma and colorectal pathways.

The government launched the strategy on 17 January 2026. Its measures cover prevention, screening, rehabilitation and palliative care, with weight on research, innovation and cooperation across sectors. Agencies received assignments to begin implementation at once: the Swedish Agency for Health and Care Services Analysis to build a structure for following up the strategy's goals and sub-goals; Socialstyrelsen to strengthen screening recommendations and the use of cancer register data and to lead a cooperation group for Swedish cancer care; and the Public Health Agency to draw up an action plan for prevention. The 2026 budget bill added 500 million kronor, bringing the total for the cancer area in 2026 to 1.5 billion kronor, to implement the strategy. The announcement states that cancer causes a quarter of all deaths in Sweden and is the leading cause of years of life lost.

Breast and cervical screening are regulated by Socialstyrelsen's binding regulations on free screening; Socialstyrelsen recommends against breast screening after 74 because no benefit has been shown, and judged the gains from tomosynthesis and breast-density assessment uncertain. Cervical screening is an HPV test, every five or seven years depending on age; about 2.5 million women are tested according to the care programme, about 340,000 have not been tested or not within the interval, and regions are sending reminders and self-sampling kits to reach them. Sweden measures the share actually tested, with a goal of 90 per cent. Bowel screening has been recommended since 2014; Stockholm and Gotland have long offered it, the other regions began from 2021, and once complete everyone aged 60 to 74 will be invited every other year to send a stool sample, with colonoscopy if blood is found. RCC estimates about 300 lives a year could be saved. Socialstyrelsen's evaluation of bowel screening is due in early 2027.

Socialstyrelsen's recommendation is that health care should not offer prostate screening with PSA alone, because the benefit does not clearly outweigh the harms; it judged that the evidence for adding a second test before biopsy, such as an MRI scan or a risk score, needs to be completed before it can recommend that, and is reviewing how and when to reassess. Organised prostate cancer testing (organiserad prostatacancertestning, OPT) is the regions' answer, supported by the regional cancer centres: two regions started in 2020 and most have begun in some form. Socialstyrelsen's own description, quoted by RCC, is that organised PSA testing means men receive clear information on the test's advantages and disadvantages and then decide individually, and is not to be confused with a screening programme. Swedish studies of ways to cut overdiagnosis in prostate testing include STHLM3 and STHLM3-MRI from Karolinska Institutet and GÖTEBORG-2 from Gothenburg.

The regional cancer centres run the studies, RCC Stockholm Gotland in Stockholm and RCC Väst with RCC Norr in their regions, the latter also testing whether blood biomarkers can refine who is invited. RCC notes that about half of lung cancer patients in Sweden are diagnosed between 70 and 79 and a fifth over 80, which bears on the upper age limit any programme would use.

The cancer register has run since 1958; national quality registers, hosted by the regional cancer centres on the INCA platform, now cover almost all cancer types, and Socialstyrelsen credits them with improving the register's completeness. A Nordic twin study led from Karolinska Institutet, using 44,788 twin pairs from the Swedish, Danish and Finnish twin registers, estimated in 2000 that heritable factors account for 42 per cent of the variation in prostate cancer risk, 35 per cent for colorectal and 27 per cent for breast cancer, and that the environment plays the principal role for most cancers; a four-country follow-up of 203,691 twins in 2016 put the heritability of cancer overall at 33 per cent. A register study of 1,672,983 Swedish girls and women published in 2020 found an adjusted incidence rate ratio for invasive cervical cancer of 0.12 among those vaccinated against HPV before 17, against the unvaccinated.

MASAI randomised 80,033 women at four screening sites in Sweden to AI-supported reading or standard double reading; at the planned safety analysis AI support found 6.1 cancers per 1,000 women screened against 5.1, with a similar false-positive rate of 1.5 per cent and 44.3 per cent less reading work, and the Swedish Cancer Society and the regional cancer centres were among its funders. ScreenTrustCAD, at Capio S:t Göran's Hospital in Stockholm, found that one radiologist plus AI was non-inferior to two radiologists in 55,581 women. STHLM3-MRI found that an MRI-first pathway found clinically significant prostate cancer in 21 per cent of men with a raised PSA randomised to it against 18 per cent with standard biopsy, while cutting insignificant cancers from 12 to 4 per cent. In treatment, the ALASCCA trial led from Karolinska Institutet found that low-dose aspirin after surgery for colorectal cancer with PI3K pathway alterations reduced three-year recurrence from 14.1 to 7.7 per cent in the primary group.

The council's recommendations rest on the ethical platform parliament adopted for health-care priorities and on TLV's health-economic assessment; treatment councils can review individual cases against a recommendation, including whether a patient should be an exception to it. The regions' joint market function negotiates agreements with companies; more than 140 cover prescription and hospital medicines.

Läkemedelsverket's website is built so that its pages do not render without running scripts, so OnCo could not read its own description of its performance, timelines or the Swedish licence route for unapproved medicines, and this page says nothing about them beyond the EU procedure. Socialstyrelsen's 2024 fact sheet publishes no survival figures, so the survival quoted is Cancerfonden's 2023 compilation from 2021 data rather than a register figure for a recent cohort, and no survival by stage is given. The interactive SVF statistics, which give results by region and diagnosis, are not read here; only the national annual report is. TLV publishes no threshold for cost per QALY, so the erdafitinib figure is one decision, not a rule. The full text of the 2026 cancer strategy, including any numeric targets, was not read; only the government's announcement was. Cancerfonden's annual research spending was not found on its site, and the figure in OnCo's country table was not verified. Europe PMC was unavailable on 3 November 2026, so DOIs were resolved through Crossref and PubMed.

The corpus has no record for Läkemedelsverket, for SBU, or for the national quality registers individually, such as the breast cancer register NKBC or the prostate register, whose annual reports are among the most detailed public cancer outcome data in Europe. It has no record for the Swedish Twin Registry or the Multi-Generation Register as resources, nor for the Swedish Family-Cancer Database. Karolinska Institutet is held only inside the Karolinska University Hospital record. GÖTEBORG-2's founding trial, the Göteborg randomised prostate screening study, and the Swedish organised testing programmes region by region are not recorded. Swedish-language care programmes in Kunskapsbanken, which govern practice in every region, are not in the guideline comparison.